International journal of gastrointestinal cancer最新文献

{"title":"CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma.","authors":"L Tamer,&nbsp;B Ercan,&nbsp;S Ercan,&nbsp;N Ateş,&nbsp;C Ateş,&nbsp;K Ocal,&nbsp;M Dirlik,&nbsp;S Aydin,&nbsp;U Atik","doi":"10.1385/IJGC:37:1:1","DOIUrl":"https://doi.org/10.1385/IJGC:37:1:1","url":null,"abstract":"<p><strong>Background: </strong>It has been reported that up to 80% of human cancers arise as a consequence of environmental exposure and host susceptibility factors. Environmental carcinogens are predominantly metabolized by the cytochrome P450 (CYP) superfamily of drug- or xenobiotic-metabolizing enzymes. Genetic variations in these enzymes affect individuals' susceptibility to carcinogens.</p><p><strong>Aim of the study: </strong>The aim of this study was to evaluate the relationship between CYP2C19 polymorphism and susceptibility to these cancers by means of CYP2C19 genotyping among Turkish subjects.</p><p><strong>Methods: </strong>DNAof subjects were isolated from leukocytes by high pure template preparation kit (Roche Diagnostics, GmbH, Mannheim, Germany) and genotypes were detected by LightCycler CYP2C19 Mutation Detection Kit by real-time PCR with LightCycler instrument (Roche Diagnostics, cat. no. 3113914).</p><p><strong>Results: </strong>Being male was associated with a 3.5-fold (OR: 4.27, CI: 2.27-8.05) and 4.27-fold (OR: 3.50, CI: 1.948-6.301) risk for colorectal and gastric carcinoma, respectively. The CYP2C19*3 heterozygote genotype was not found in either gastric or colorectal carcinoma patients. Although the frequency of CYP2C19*2 heterozygote genotype is high in patients with gastric and colorectal carcinoma, it is not significantly associated with cancer (OR: 1.79, CI: 0.829-3.865 and OR: 1.998, CI: 0.961-4.154, respectively).</p><p><strong>Conclusion: </strong>Although the frequency of CYP2C19*2 heterozygote genotype is high in our patients with gastric and colorectal carcinoma, there is no the relationship between CYP2C19 polymorphism and susceptibility to these cancer.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"37 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:37:1:1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26600105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Solitary\" necrotic nodule of the liver: an enigmatic entity mimicking malignancy.","authors":"Agatha I Kondi-Pafiti,&nbsp;Dimitra S Grapsa,&nbsp;Evi D Kairi-Vasilatou,&nbsp;Dionysios K Voros,&nbsp;Vasilios E Smyrniotis","doi":"10.1007/s12029-007-0002-8","DOIUrl":"https://doi.org/10.1007/s12029-007-0002-8","url":null,"abstract":"<p><strong>Aim: </strong>The aim of the study is to further investigate the clinicopathological features of solitary necrotic nodules.</p><p><strong>Material and methods: </strong>Twenty-three archived cases of solitary necrotic nodule of the liver, which were preoperatively misdiagnosed as liver metastases were studied. The pathological findings were correlated with the clinical data of the patients.</p><p><strong>Results: </strong>The nodules were solitary in 20 cases and multiple (2) in three cases, and measured from 0.5-1.5 cm in diameter. Twenty-one cases were located in the right lobe of the liver (91.6%) and two in the left lobe (8.69%). Twenty nodules were found in the subcapsular region (86.95%), while three nodules were located within the hepatic parenchyma (13.04%). More then half of our cases (12) were accompanied by extended calcification. Granulomatous tissue resembling \"burnt-out\" parasitic granulomas was found in three cases.</p><p><strong>Conclusions: </strong>Solitary necrotic nodules of the liver often mimic malignancy in abdominal imaging. Thus, permanent histopathology of the operative specimen remains the only accurate method of diagnosis. Their pathogenesis is most likely variable, and most reported cases are linked either to a parasitic or a vascular origin. Despite the designation of these lesions as \"solitary\" they may occasionally be multiple. In addition to the standard histological criteria of solitary necrotic nodules, the relatively small size (15 mm or less) and the frequent presence of calcifications seem to further characterize this enigmatic entity. Solitary necrotic nodule should be included in the differential diagnosis of small liver lesions with extensive necrosis.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"37 2-3","pages":"74-8"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12029-007-0002-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27009120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatofibrosarcoma protuberans and small bowel adenocarcinoma: coincidental occurrence or genetic association?","authors":"Ashley Sumrall,&nbsp;Nilam Soni","doi":"10.1007/s12029-007-9000-0","DOIUrl":"https://doi.org/10.1007/s12029-007-9000-0","url":null,"abstract":"<p><p>A case of multiple malignancies in a 41 year old African American man is described. After surgical excision and radiotherapy of dermatofibrosarcoma protuberans, the patient developed small bowel adenocarcinoma. We propose a common etiology to these canceres via tumor suppressor gene p53.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"37 4","pages":"146-8"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12029-007-9000-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27206309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality predictions for esophageal, stomach, and pancreatic cancer, Ireland, up to 2015.","authors":"P O'Lorcain,&nbsp;S Deady,&nbsp;H Comber","doi":"10.1385/IJGC:37:1:15","DOIUrl":"https://doi.org/10.1385/IJGC:37:1:15","url":null,"abstract":"<p><strong>Background and aim of the study: </strong>An analysis was undertaken to predict numbers of esophageal, stomach, and pancreatic cancer deaths and their World age standardized mortality rates (WASMRs) per 100,000 person years (100,000 PY-1) in Ireland for the years 2005, 2010 and 2015.</p><p><strong>Methods: </strong>Linear and log-linear Poisson regression models were applied to 1950-2002 Irish cancer mortality data.</p><p><strong>Results: </strong>By 2015, esophageal cancer WASMR for males is expected to rise to 9.1 100,000 PY-1, but for females to fall to 2.3 100,000 PY-1. In women under 65 yr, the WASMR is expected to decline to 0.8 100,000 PY-1 but to increase to 3.6 100,000 PY-1 in men. The stomach cancer WASMR for males is predicted to decrease to 5.3 100,000 PY-1 and for females to 2.9 100,000 PY-1. In males under 65 yr, the WASMR is predicted to fall to 1.7 100,000 PY-1 and to 1.0 100,000 PY-1 in women. The male WASMR for pancreatic cancer is predicted to decrease to 5.9 100,000 PY-1 and to 4.7 100,000 PY-1 in women. In men under 65 yr, the WASMR is predicted to drop to 1.7 100,000 PY-1 and to fall in women to 1.2 100,000 PY-1.</p><p><strong>Conclusions: </strong>Apart from male esophageal cancer, the findings would indicate that declines in Irish WASMRs for these three cancer types are expected to occur by 2015.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"37 1","pages":"15-25"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:37:1:15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26600107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ulcerous change decreases the accuracy of endoscopic ultrasonography diagnosis for the invasive depth of early gastric cancer.","authors":"K Akashi,&nbsp;H Yanai,&nbsp;J Nishikawa,&nbsp;M Satake,&nbsp;Y Fukagawa,&nbsp;T Okamoto,&nbsp;I Sakaida","doi":"10.1007/s12029-007-9004-9","DOIUrl":"https://doi.org/10.1007/s12029-007-9004-9","url":null,"abstract":"<p><strong>Background: </strong>With the development of endoscopic submucosal dissection, an expansion of the criteria for local treatment was suggested for lesions with ulcerous changes or undifferentiated-type adenocarcinoma.</p><p><strong>Aim of the study: </strong>To determine the efficacy of endoscopic ultrasonography for such lesions, we retrospectively analyzed factors that influenced accurate diagnosis by endoscopic ultrasonography of the depth of tumor invasion.</p><p><strong>Methods: </strong>We investigated 267 gastric adenocarcinomas for which histopathological results were obtained by endoscopic mucosal resection or gastrectomy. The lesions were divided into four groups by histological type and the presence of ulcerous changes. Five clinicopathological factors were assessed for their possible associations with incorrect diagnosis.</p><p><strong>Results: </strong>The positive predictive value (PPV) for cancer limited within the mucosa (endoscopic ultrasonography, EUS-M) and cancer invaded into the submucosal layer (EUS-SM) were 88.0% (125 of 142 lesions) and 60.0% (30 of 50 lesions), respectively. The lesions diagnosed as EUS-M/SM borderline (37 lesions) included 19 lesions (51.4%) of M cancer and 17 lesions (45.9%) of SM cancer. In logistic analysis, ulcerous changes (p < 0.0001) and macroscopic classification (p = 0.0284) were factors that caused incorrect diagnosis by endoscopic ultrasonography. In the group having differentiated-type adenocarcinoma with ulcerous changes, the PPV of EUS-SM was 25% (3 of 12), and there was a significant difference (p < 0.05) between the EUS-SM of this group and that of the differentiated-type adenocarcinoma without ulcerous changes.</p><p><strong>Conclusion: </strong>The accuracy of endoscopic ultrasonography tumor staging was not sufficient for the lesions with ulcerous changes in our study. Therefore, we should be careful to perform endoscopic submucosal dissection for lesions with ulcerous changes.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"37 4","pages":"133-8"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12029-007-9004-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27118907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations.","authors":"Jon P Fryzek,&nbsp;David H Garabrant,&nbsp;Maryjean Schenk,&nbsp;Margaret Kinnard,&nbsp;Joel K Greenson,&nbsp;Fazlul H Sarkar","doi":"10.1007/s12029-007-9005-8","DOIUrl":"https://doi.org/10.1007/s12029-007-9005-8","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is a major contributor to cancer mortality. Studies suggest that a few risk factors, including cigarette smoking, body mass index, having a relative with pancreatic cancer, and diabetes may be related to pancreatic cancer risk.</p><p><strong>Aim of the study: </strong>We conducted a case-control study in southeastern Michigan to examine the relation between the above mentioned risk factors and mutations of the K-ras oncogene and p53 tumor suppressor gene.</p><p><strong>Methods: </strong>Two hundred forty-five patients with newly diagnosed pancreatic cancer and 420 general population controls were enrolled in the study. For this analysis, all case subjects were restricted to the pancreatic cancer patients that had tissue blocks available for study (n = 51). In-person interviews were conducted to ascertain information on demographic and lifestyle factors. Adjusted logistic regression analyses were conducted to compare various subject characteristics of pancreatic cancer patients with K-ras and p53 mutations and their subtypes to the characteristics of the general population controls.</p><p><strong>Results: </strong>Smoking (adjusted odds ratio [aOR] = 2.0; 95% confidence interval [95%CI] = 0.9-4.3) and diabetes diagnosed 5 or more years before interview (aOR = 3.4; 95%CI = 1.3-8.8) were associated with pancreatic cancer patients positive for K-ras codon 12 mutations, but not with pancreatic cancer patients negative for K-ras codon 12 mutations. On the other hand, none of the examined risk factors were meaningfully related to patients with p53 mutations.</p><p><strong>Conclusions: </strong>This study suggests that some recognized risk factors for pancreatic cancer may also be associated with K-ras codon 12 mutations. However, further large-scale studies are warranted.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":" ","pages":"139-45"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12029-007-9005-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40821063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial DNA mutations in pancreatic cancer.","authors":"Keyanoosh Kassauei,&nbsp;Nils Habbe,&nbsp;Michael E Mullendore,&nbsp;Collins A Karikari,&nbsp;Anirban Maitra,&nbsp;Georg Feldmann","doi":"10.1007/s12029-007-0008-2","DOIUrl":"https://doi.org/10.1007/s12029-007-0008-2","url":null,"abstract":"<p><strong>Background: </strong>Somatic mutations of mitochondrial DNA (mtDNA) are increasingly being recognized in many human cancers, but automated sequencing of 16.5 kb of DNA poses an onerous task. We have recently described an oligonucleotide microarray (MitoChip) for rapid and accurate sequencing of the entire mitochondrial genome (Zhou et al., J Mol Diagnostics, 8: 9_14, 2006), greatly facilitating the analysis of mtDNA mutations in cancer. In this report, we perform a comprehensive cataloging of somatic mutations in the mitochondrial genome of human pancreatic cancers using our novel array-based approach.</p><p><strong>Materials and methods: </strong>MitoChip analysis was performed on DNA isolated from 15 histologically confirmed resection specimens of pancreatic ductal adenocarcinomas. In all cases, matched nonneoplastic pancreatic tissue was obtained as germline control for mtDNA sequence. DNA was extracted from snap-frozen cryostat-embedded specimens and hybridized to the sequencing microarray after appropriate polymerase chain reaction amplification and labeling steps. The vast majority of somatic mutational analyses of mtDNA in human cancers utilize lymphocyte DNA as germline control, without excluding the potential for organ-specific polymorphisms. Therefore, we also examined a series of 15 paired samples of DNA obtained from nonneoplastic pancreata and corresponding EBV-immortalized lymphoblastoid cell lines to determine whether lymphocyte DNA provides an accurate surrogate for the mtDNA sequence of pancreatic tissue.</p><p><strong>Results: </strong>We sequenced 497,070 base pairs of mtDNA in the 15 matched samples of pancreatic cancer and nonneoplastic pancreatic tissue, and 467,269 base pairs (94.0%) were assigned by the automated genotyping software. All 15 pancreatic cancers demonstrated at least one somatic mtDNA mutation compared to the control germline DNA with a range of 1-14 alterations. Of the 71 somatic mutations observed in our series, 18 were nonsynonymous coding region alterations (i.e., resulting in an amino acid change), 22 were synonymous coding region alterations, and 31 involved noncoding mtDNA segments (including ribosomal and transfer RNAs). Overall, somatic mutations in the coding region most commonly involved the ND4, COI, and CYTB genes; of note, an A-G transition at nucleotide position 841 in the 12sRNA was observed in three independent samples. In the paired analysis of nonneoplastic pancreata and lymphoblastoid cell line DNA, 14 nucleotide discrepancies were observed out of 226,876 nucleotide sequences (a concordance rate of 99.99%), with 9 samples demonstrating a perfect match across all bases assigned.</p><p><strong>Conclusions: </strong>Our findings confirm that somatic mtDNA mutations are common in pancreatic cancers, and therefore, have the potential to be a clinically useful biomarker for early detection. Further, our studies confirm that lymphocyte DNA is an excellent, albeit not perfect, surrogate","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"37 2-3","pages":"57-64"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12029-007-0008-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27009118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of CYP2C9*2 allele in HepG2 cell line.","authors":"Jiezhong Chen,&nbsp;Kenneth Raymond","doi":"10.1007/s12029-007-0003-7","DOIUrl":"https://doi.org/10.1007/s12029-007-0003-7","url":null,"abstract":"<p><strong>Background: </strong>Hepatoma is caused by many factors including alcohol, chemicals, viral infection, and chronic inflammation. Cytochrome P450 polymorphism plays an important role in its pathogenesis. CYP2D6, CYP2E1, and CYP1A1 have been identified to be related with hepatic carcinogenesis and tumor size and stage. However, no studies have been performed on CYP2C9, a major CYP in the liver and hepatoma.</p><p><strong>Aim of the study: </strong>To identify if there is polymorphism of CYP2C9 in a HepG2 cell line.</p><p><strong>Methods: </strong>A pair of primers was used to clone CYP2C9 exon 3 region and subsequently sequenced. The sequence was compared to normal CYP2C9 for identification of any mutation.</p><p><strong>Results: </strong>A point mutation was identified. It was located in the amino acid number 144 of CYP2C9 protein with the change of normal amino acid arginine into cysteine, which is the same as identified in poor metabolism patients as homozygous CYP2C9*2.</p><p><strong>Conclusions: </strong>There is a mutation (CYP2C9*2/ CYP2C9*2) in a HepG2 cell line. Thus, polymorphism of CYP2C9 may also be involved in the carcinogenesis of hepatoma as CYPs2D6 and 2E1.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"37 2-3","pages":"79-83"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12029-007-0003-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27009121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estrogen and progesterone receptors expression in gastrointestinal stromal tumors and intramural gastrointestinal leiomyomas.","authors":"Sergey V Brodsky,&nbsp;Cecilia Gimenez,&nbsp;Chandrani Ghosh,&nbsp;Myron Melamed,&nbsp;Gita Ramaswamy","doi":"10.1007/s12029-007-9003-x","DOIUrl":"https://doi.org/10.1007/s12029-007-9003-x","url":null,"abstract":"<p><p>Gastrointestinal stromal tumors (GISTs) and leiomyomas of the gastrointestinal tract both may present as intramural smooth muscle cell tumors. Immunohistochemically, these tumors demonstrate different spectrums of protein expression, which helps in differential diagnosis. Leiomyomas of the uterine type are similar by the spectrum of protein expression to gastrointestinal leiomyomas, but they express in addition both estrogen (ER) and progesterone (PR) receptors, which makes hormonal therapy possible for these tumors. In the current study, we investigated expression of ER and PR in GISTs and intramural gastrointestinal leiomyomas. Our data demonstrate that none of the 22 cases of gastrointestinal leiomyomas nor 19 cases of GIST were positive for either ER or PR expression. In contrast, leiomyomas of the uterine type were strongly positive for both ER and PR. Our data demonstrate that GIST and gastrointestinal leiomyomas differ from leiomyomas of the uterine type by the expression of ER and PR. Immunostaining for ER and PR may be a useful tool to distinguish these tumors and more precisely to plan further clinical interventions.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":" ","pages":"129-32"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12029-007-9003-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41023450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient satisfaction with quality of life as a predictor of survival in pancreatic cancer.","authors":"Christopher G Lis,&nbsp;Digant Gupta,&nbsp;James F Grutsch","doi":"10.1385/IJGC:37:1:35","DOIUrl":"https://doi.org/10.1385/IJGC:37:1:35","url":null,"abstract":"<p><strong>Background: </strong>The goal of this study was to evaluate the association between patient satisfaction with quality of life (QoL) and survival in pancreatic cancer patients undergoing care in a community hospital comprehensive cancer center.</p><p><strong>Patients and methods: </strong>A consecutive case series of 55 cases of histologically confirmed pancreatic cancer treated at Cancer Treatment Centers of America at Midwestern Regional Medical Center was studied between 04/01 and 11/04. The Quality of Life Index (QLI) was utilized to assess patient satisfaction with QoL. QLI measures global QoL as well as the QoL in four major subscales: health and physical, social and economic, psychological and spiritual, and family. All scores range from 0 to 30 with higher scores indicating a better QoL. The Kaplan-Meier method was used to calculate survival. Log-rank test was used to study the equality of survival distributions. Multivariate Cox regression analyses were then performed to evaluate the joint prognostic significance of those QoL and clinical factors that were shown to be prognostic in univariate analyses.</p><p><strong>Results: </strong>Of the 55 patients, 28 were newly diagnosed and 27 had prior treatment history. The median age was 55 yr (range 33-74 yr). Amajority (34) had stage IV disease at diagnosis. Health and physical subscale, family subscale, and global QoL were significantly associated with survival upon univariate analysis. Health and physical subscale was marginally significant upon multivariate analysis after controlling for the effects of stage at diagnosis.</p><p><strong>Conclusions: </strong>We found that baseline patient satisfaction with QoL, as measured by the QLI, provides useful prognostic information in patients with pancreatic cancer. While these findings require further investigation in large patient cohorts, they may have important implications for patient stratification in clinical trials, as well as aid in clinical decision-making.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"37 1","pages":"35-44"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:37:1:35","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26600023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}